Login (DCU Staff Only)
Login (DCU Staff Only)

DORAS | DCU Research Repository

Explore open access research and scholarly works from DCU

Advanced Search

Investigating combinations of tyrosine kinase inhibitors and antibody-drug conjugates, and mechanisms of resistance, in HER2-expressing breast cancers

Ashfield, Niall orcid logoORCID: 0000-0002-1536-5366 (2026) Investigating combinations of tyrosine kinase inhibitors and antibody-drug conjugates, and mechanisms of resistance, in HER2-expressing breast cancers. PhD thesis, Dublin City University.

Abstract
HER2-targeting tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) have significantly improved patient prognoses. The ADC T-DXd has proven successful in HER2-overexpressing (HER2+) breast cancer, HER2-low and -ultralow breast cancer, and HER2+ solid cancers outside breast. TKIs and ADCs are not currently prescribed together but there is substantial rationale for their combination. Acquired resistance to ADCs is also an emerging clinical problem. This work focusses on identifying promising TKI/ADC combinations for HER2+ breast cancer and novel resistance mechanisms to T-DXd, Synergy was observed with irreversible TKIs afatinib and neratinib plus T-DM1 or T-DXd in oestrogen receptor-negative (ER-)/HER2+ cell lines; and with almost all TKI/T-DXd combinations in ER+ cell lines. TKI/T-DXd synergy was observed in HER2+/ER+ BT474 3D spheroid models. In vivo work showed strong potency of T-DXd alone in BT474 xenografts, despite limited efficacy in this cell line in vitro. The addition of neratinib did not enhance T-DXd efficacy in vivo at the concentrations tested. TKI co-treatment can affect internalisation rates of ADCs, though this does not always correlate with cytotoxic synergy or antagonism of TKI/ADC combinations. A T-DXd-resistant HCC1569 cell line (HCC1569-TDXd) was developed with a >800-fold increase in resistance to T-DXd that remained sensitive to other HER2-targeting therapies. Signalling through HER family members and downstream Akt and ERK pathways was decreased. ADC internalisation rates were decreased, as was expression of genes associated with endocytosis (CAV1, CLTC) and endosomal trafficking (RAB7A). HER2 TKI co-treatments displayed additivity rather than synergy in combination with T-DXd in HCC1569-TDXd, but the MEK inhibitor trametinib showed potential with T-DXd in this model. HCC1569-TDXd showed major alterations in energy metabolism, spliceosome activity, and MRP1 (drug efflux pump) expression. In conclusion, this work has suggested promise of TKI/ADC combinations in vitro and in vivo, and identified potential mechanisms of resistance to T-DXd in HER2+ breast cancer.
Metadata
Item Type:Thesis (PhD)
Date of Award:23 October 2026
Refereed:No
Additional Information:Contact denis.collins@dcu.ie for access queries
Supervisor(s):Collins, Denis M., Mahdi, Amira F and Crown, John
Subjects:Biochemistry, Genetics and Molecular Biology > Biochemistry, Genetics and Molecular Biology (miscellaneous)
Biochemistry, Genetics and Molecular Biology > Biotechnology
DCU Faculties and Centres:DCU Faculties and Schools > Faculty of Science and Health
DCU Faculties and Schools > Faculty of Science and Health > School of Biotechnology
School, Faculty or Unit:Faculty of Science & Health
Faculty of Science & Health > School of Biotechnology
Use License:This item is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 License. View License
Funders:Research Ireland Enterprise Partnership Scheme Award (EPSPG-2021-243),, The Cancer Clinical Research Trust (CCRT)
ID Code:32638
Deposited On:09 Nov 2026 14:09 by Denis Collins . Last Modified 09 Nov 2026 14:09
Documents

Full text available as:

[thumbnail of NA_final approved thesis_21269771_28.05.26.pdf]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
14MB
Downloads

Downloads

Downloads per month over past year

Archive Staff Only: edit this record